David Bottomley
Leeds Teaching Hospitals NHS Trust
Quality of lifeInternal medicineRadiologyUrologySurgeryOncologyRandomized controlled trialHazard ratioExternal beam radiotherapyProstateBrachytherapyProstate brachytherapyProstate cancerDocetaxelImplantNuclear medicineIn patientCastration resistantRadiation therapyIodineMedicine
Publications 82
#1Chris Parker (The Royal Marsden NHS Foundation Trust)H-Index: 83
Last. Sten NilssonH-Index: 54
view all 9 authors...
ABSTRACT Aim: In ALSYMPCA, the first-in-class alpha-emitter Ra-223 had a highly favorable safety profile and was well tolerated (Parker et al. NEJM 2013). Safety monitoring of Ra-223 is essential for a complete safety profile. Reported here are safety results of a post hoc analysis from an interim review of ∼1.5 years after the last pt's last injection. Methods: Pts were to enter designated follow-up starting 4 weeks after their last injection until 3 years after first injection. Pts were to be ...
2 CitationsSource
#1Hashim U. Ahmed (UCL: University College London)H-Index: 62
#2Viktor BergeH-Index: 20
Last. Mark Emberton (UCL: University College London)H-Index: 80
view all 16 authors...
Tissue-preserving focal therapies, such as brachytherapy, cryotherapy, high- intensity focused ultrasound and photodynamic therapy, aim to target individual cancer lesions rather than the whole prostate. These treatments have emerged as potential interventions for localized prostate cancer to reduce treatment-related adverse- effects associated with whole-gland treatments, such as radical prostatectomy and radiotherapy. In this article, the Prostate Cancer RCT Consensus Group propose that a nove...
43 CitationsSource
#1Chris Parker (The Royal Marsden NHS Foundation Trust)H-Index: 83
Last. Sten Nilsson (Karolinska University Hospital)H-Index: 54
view all 8 authors...
5070 Background: Ra-223, an alpha-emitting pharmaceutical, significantly improved overall survival and was well tolerated in ALSYMPCA (Parker, NEJM2013). Long-term safety monitoring of Ra-223 is essential to build a complete safety profile and identify any association with secondary malignancies. Here we report adverse events (AEs) from ALSYMPCA patients (pts) ~1.5 y after last pt’s final injection (inj). Methods: All ALSYMPCA pts were to enter designated follow-up starting 4 wk after each pt’s ...
4 CitationsSource
#1Peter D. DickinsonH-Index: 1
#2Jahangeer MalikH-Index: 7
Last. James P WylieH-Index: 21
view all 8 authors...
Objective To report the outcomes of >1000 men with low-risk prostate cancer treated with low-dose-rate (LDR) brachytherapy at three large UK cancer centres. Patients and Methods A total of 1038 patients with low-risk prostate cancer (prostate-specific antigen [PSA] ≤10 ng/mL, Gleason score 6, ≤T2b disease) were treated with LDR iodine 125 (I-125) brachytherapy between 2002 and 2007. Patients were treated at three UK centres. PSA and clinical follow-up was performed at each centre. Biochemical re...
15 CitationsSource
#1David P. Dearnaley (ICR: Institute of Cancer Research)H-Index: 108
#2Gordana Jovic (UCL: University College London)H-Index: 19
Last. Matthew R. Sydes (UCL: University College London)H-Index: 70
view all 17 authors...
Summary Background The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of fo...
252 CitationsSource
#1Hima Bindu Musunuru (St James's University Hospital)H-Index: 12
#2M. Mason (St James's University Hospital)H-Index: 2
Last. Ann Henry (St James's University Hospital)H-Index: 32
view all 10 authors...
Abstract Aims Prostate brachytherapy may be associated with a lower risk of radiation-induced second primary cancer (SPC) as a significantly smaller volume of normal tissue is irradiated when compared with external beam techniques. Limited data are available as it has been a routine treatment option for less than 20 years. This study identified cases of SPC in patients who underwent I-125 prostate brachytherapy as monotherapy in a single institution. Materials and methods SPC incidence was retri...
17 CitationsSource
#1Sten Nilsson (Karolinska University Hospital)H-Index: 27
#1Sten Nilsson (Karolinska University Hospital)H-Index: 54
Last. Chris Parker (The Royal Marsden NHS Foundation Trust)H-Index: 83
view all 8 authors...
9 Background: Ra-223 is a first-in-class alpha-emitting pharmaceutical recently Food and Drug Administration approved for treatment (tx) of patients (pts) with CRPC and symptomatic bone metastases (mets). In ALSYMPCA, Ra-223 significantly improved overall survival by 3.6 months versus placebo (pbo) (HR = 0.70; 95% CI, 0.58-0.83; P < 0.001) and was well tolerated. Reported here are long-term safety data ~1.5 years after the last pt’s final injection (inj) from the entire ALSYMPCA safety populatio...
14 CitationsSource
#1Joe M. O'SullivanH-Index: 53
#2Chris ParkerH-Index: 83
Last. Sten NilssonH-Index: 54
view all 10 authors...